AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26525030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu Chan Xue Jing
Number of subjects: 86
Study 26525030 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic medical abortion)
Number of subjects: 86
Study 24490242 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 1988
Study 24490242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1988
Study 21543987 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 87
Study 21543987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 18471324 — intervention group
Group type: EXPERIMENTAL
Intervention: Online formative assessment
Number of subjects: 0
Study 18471324 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary learning material (not specified if online or other forms)
Number of subjects: 0
Study 18471324 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical material
Number of subjects: 0
Study 17101625 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation and nutritional counseling
Number of subjects: 25
Study 11889149 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/d
Number of subjects: 331
Study 11889149 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 10 mg/d
Number of subjects: 331
Study 11889149 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/d and Alendronate (ALN) 10 mg/d combined
Number of subjects: 331
Study 11889149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 9462526 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) at therapeutic concentrations
Number of subjects: 50
Study 9462526 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.25 U/mL)
Number of subjects: 50
Study 9462526 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (1 ng/mL)
Number of subjects: 50
Study 9462526 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 7622771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg b.i.d.) + Coamoxiclav (1 g b.i.d.) for 3 weeks
Number of subjects: 118
Study 7622771 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d.) + Coamoxiclav (1 g b.i.d.) for 6 weeks
Number of subjects: 118
Study 2239134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine
Number of subjects: 0
Study 2239134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 2239134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 379929 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and hormonal therapy (alternating chemotherapy and tamoxifen)
Number of subjects: 0
Study 379929 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients radiated in the same period who failed to meet entry criteria)
Number of subjects: 0
Study 30411128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealing (Group A)
Number of subjects: 90
Study 30411128 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive resin filling (Group B)
Number of subjects: 90
Study 30411128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluoride coating combined with pit and fissure sealing (Group C)
Number of subjects: 90
Study 30411128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluoride combined with preventive resin filling (Group D)
Number of subjects: 90
Study 30411128 — intervention group
Group type: COMPARATOR
Intervention: Control group with daily nursing brushing (Group E)
Number of subjects: 90
Study 26361879 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus MTX
Number of subjects: 205
Study 26361879 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 205
Study 24761456 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 95
Study 24761456 — intervention group
Group type: COMPARATOR
Intervention: Summary control
Number of subjects: 95
Study 22374183 — intervention group
Group type: COMPARATOR
Intervention: Troponin I <0.010 μg/L (n=2663)
Number of subjects: 6189
Study 22374183 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I ≥0.040 μg/L (n=497)
Number of subjects: 6189
Study 22374183 — intervention group
Group type: COMPARATOR
Intervention: NT‐proBNP <387 ng/L
Number of subjects: 6189
Study 22374183 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP >1402 ng/L
Number of subjects: 6189
Study 20812540 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal instillation of a lidocaine/prilocaine cream (EMLA R)
Number of subjects: 372
Study 20812540 — intervention group
Group type: COMPARATOR
Intervention: 2.5% lidocaine gel
Number of subjects: 372
Study 20812540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (10 gr/100 ml)
Number of subjects: 372
Study 19127003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 17148517 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal magnetic corsets
Number of subjects: 60
Study 17148517 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (lumbar traction, medium frequency electrotherapy, and massage)
Number of subjects: 60
Study 12670837 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 0
Study 12670837 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate
Number of subjects: 0
Study 10485531 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigating balanced salt solution supplemented with vancomycin (10 microg/ml)
Number of subjects: 118
Study 10485531 — intervention group
Group type: COMPARATOR
Intervention: Control group received salt solution only
Number of subjects: 118
Study 9139272 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart infarction with Q wave
Number of subjects: 50
Study 9139272 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart infarction without Q wave
Number of subjects: 50
Study 9139272 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 50
Study 1657505 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐[1‐13C]leucine continuous infusion
Number of subjects: 0
Study 1657505 — intervention group
Group type: EXPERIMENTAL
Intervention: Flooding amount of L‐[1‐13C]leucine
Number of subjects: 0
Study 1657505 — intervention group
Group type: EXPERIMENTAL
Intervention: Flooding amount of L‐[1‐13C]phenylalanine (0.05 g/kg)
Number of subjects: 0
Study 1657505 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous injection of leucine
Number of subjects: 0
Study 1657505 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous injection of valine
Number of subjects: 0
Study 1657505 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 0.05 g of L‐leucine/kg
Number of subjects: 0
Study 7231912 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 68
Study 7231912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 68
Study 7231912 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 68
Study 12519036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen isobutanolammonium
Number of subjects: 30
Study 12519036 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine hydrochloride
Number of subjects: 30
Study 29907211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 29907211 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 26917157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate tea (MT)
Number of subjects: 12
Study 26917157 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 12
Study 24903461 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training group (FG)
Number of subjects: 21
Study 24903461 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study 24903461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 21949192 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI), n = 391
Number of subjects: 772
Study 21949192 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving two leaflets about alcohol, n = 381
Number of subjects: 772
Study 20384428 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 91
Study 20384428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 18418433 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral glucose load (75 g)
Number of subjects: 19
Study 18418433 — intervention group
Group type: COMPARATOR
Intervention: Isovolumetric sham drink
Number of subjects: 19
Study 15825072 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice per day
Number of subjects: 549
Study 15825072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 12152802 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICGA) with infrared fundus camera
Number of subjects: 38
Study 10782623 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG) diagnosis
Number of subjects: 1993
Study 10782623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation syndrome (PEX)
Number of subjects: 1993
Study 10782623 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple ocular hypertension
Number of subjects: 1993
Study 8877661 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 1 (E-1; n = 80) received a new toothbrush, toothpaste, and instruction
Number of subjects: 240
Study 8877661 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 2 (E-2; n = 80) received toothbrush, toothpaste, dental floss, and instruction
Number of subjects: 240
Study 8877661 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; n = 80) received only dental examinations
Number of subjects: 240
Study 8877661 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (E-1 and E-2) during the preventive program
Number of subjects: 240
Study 8877661 — intervention group
Group type: EXPERIMENTAL
Intervention: After the instructional program (6 months later)
Number of subjects: 240
Study 1819034 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA in a routine dose
Number of subjects: 110
Study 1819034 — intervention group
Group type: COMPARATOR
Intervention: EAA in a much smaller dosage
Number of subjects: 110
Study 6352887 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 99
Study 6352887 — intervention group
Group type: COMPARATOR
Intervention: Chlorothiazide
Number of subjects: 99
Study 6352887 — intervention group
Group type: EXPERIMENTAL
Intervention: High birth weight
Number of subjects: 99
Study 6352887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initial mean airway pressure
Number of subjects: 99
Study 6352887 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of intraventricular hemorrhage
Number of subjects: 99
Study 6352887 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuresis
Number of subjects: 99
Study 31078650 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch with real-time feedback
Number of subjects: 80
Study 27340939 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Vestibular Rehabilitation Therapy (VRT) + Canalith Repositioning Maneuver (CRM)
Number of subjects: 14
Study 27340939 — intervention group
Group type: COMPARATOR
Intervention: Canalith Repositioning Maneuver (CRM) only
Number of subjects: 14
Study 27252251 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA therapy
Number of subjects: 0
Study 23223966 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-high insert (DH)
Number of subjects: 40
Study 23223966 — intervention group
Group type: COMPARATOR
Intervention: Medial-pivot insert (MP)
Number of subjects: 40
Study 22574593 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sijunzi Decoction (MSD)
Number of subjects: 32
Study 22574593 — intervention group
Group type: COMPARATOR
Intervention: Control (cleaning enema)
Number of subjects: 32
Study 20145567 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of quadriceps and triceps surae muscles for 10 minutes
Number of subjects: 17
Study 20145567 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no stretching)
Number of subjects: 17
Study 18042313 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 14
Study 18042313 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 14
Study 15808754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (defined as glucose > or =7.8 mmol/l or 140 mg/dl)
Number of subjects: 460
Study 15808754 — intervention group
Group type: COMPARATOR
Intervention: Non-hyperglycemic patients (glucose < 7.8 mmol/l)
Number of subjects: 460
Study 12154206 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 126
Study 12154206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 126
Study 12154206 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (SSZ)
Number of subjects: 126
Study 9925069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (3 mEq/kg NaHCO3)
Number of subjects: 6
Study 9925069 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (1 mEq/kg NaCl)
Number of subjects: 6
Study 8431099 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of methylphenidate per day
Number of subjects: 38
Study 8431099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3309002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioprosthesis (Hancock porcine heterograft)
Number of subjects: 575
Study 3309002 — intervention group
Group type: COMPARATOR
Intervention: Mechanical prosthesis (Björk-Shiley spherical disc valve)
Number of subjects: 575
Study 31325499 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced food without additives (group 1)
Number of subjects: 159
Study 31325499 — intervention group
Group type: COMPARATOR
Intervention: Supermarket food (group 2)
Number of subjects: 159
Study 29332101 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolution Taping Method (CTM)
Number of subjects: 28
Study 29332101 — intervention group
Group type: COMPARATOR
Intervention: Non-Convolution Taping Method (NCTM)
Number of subjects: 28
Study 27552723 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust and social engagement
Number of subjects: 0
Study 27552723 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy mistrust
Number of subjects: 0
Study 25631734 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-monitored group (n=17)
Number of subjects: 34
Study 25631734 — intervention group
Group type: COMPARATOR
Intervention: Non-BIS-monitored group (n=17)
Number of subjects: 34
Study 22615323 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental challenge with approximately 1800 Plasmodium falciparum-parasitized red blood cells (pRBCs)
Number of subjects: 10
Study 22615323 — intervention group
Group type: COMPARATOR
Intervention: Control group inoculated with <180 pRBCs
Number of subjects: 10
Study 20125070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric levobupivacaine (13.5 mg, intrathecally in 3 mL)
Number of subjects: 0
Study 20125070 — intervention group
Group type: COMPARATOR
Intervention: Isobaric levobupivacaine (13.5 mg, intrathecally in 3 mL)
Number of subjects: 0
Study 18429659 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 18429659 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α plus low-dose cytarabine
Number of subjects: 0
Study 18429659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness ratios
Number of subjects: 0
Study 15953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization method specified
Number of subjects: 28
Study 15953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation concealment
Number of subjects: 28
Study 15953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blinding
Number of subjects: 28
Study 15953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of withdrawals and dropouts
Number of subjects: 28
Study 15953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to treat analysis
Number of subjects: 28
Study 15953951 — intervention group
Group type: EXPERIMENTAL
Intervention: Jadad score
Number of subjects: 28
Study 11850261 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of artesunate (0 to 250 mg) with a curative dose of oral mefloquine
Number of subjects: 47
Study 11850261 — intervention group
Group type: COMPARATOR
Intervention: Single doses of artesunate higher than 2 mg/kg
Number of subjects: 47
Study 10069672 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg/day)
Number of subjects: 28
Study 10069672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8673823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (6-monthly regime)
Number of subjects: 335
Study 8673823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (multiple doses)
Number of subjects: 335
Study 8673823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (at least three doses)
Number of subjects: 335
Study 8673823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (annual treatment interval)
Number of subjects: 335
Study 1885274 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 44
Study 1885274 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate-meglumine
Number of subjects: 44
Study 6416853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 25-hydroxyvitamin D3 treatment
Number of subjects: 48
Study 6416853 — intervention group
Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 48
Study 6416853 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in absorption on treatment
Number of subjects: 48
Study 6416853 — intervention group
Group type: EXPERIMENTAL
Intervention: 51Cr EDTA clearance measurement
Number of subjects: 48
Study 30794762 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii training
Number of subjects: 32
Study 30794762 — intervention group
Group type: COMPARATOR
Intervention: Task-specific training
Number of subjects: 32
Study 30794762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 30808623 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA (combination of sulfasalazine, low-dose methotrexate, and initially high, step-down prednisolone)
Number of subjects: 155
Study 30808623 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine monotherapy (SSZ)
Number of subjects: 155
Study 30808623 — intervention group
Group type: COMPARATOR
Intervention: General population reference sample
Number of subjects: 155
Study 27731538 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (50 mg/m2)
Number of subjects: 80
Study 27731538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27731538 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 80
Study 27731538 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 80
Study 25564804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg body weight + immunomodulatory agent (azathioprine 1.5-3 mg/kg body weight per day or methotrexate 10-25 mg/week) continued up to week 54
Number of subjects: 99
Study 25564804 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (IFX) 5 mg/kg body weight + immunomodulatory agent discontinued after 26 weeks
Number of subjects: 99
Study 25564804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 99
Study 24413701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian spatial random-effects modeling approach
Number of subjects: 0
Study 24413701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian spatial modeling
Number of subjects: 0
Study 22984910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) plus self-lymphatic drainage (SLD)
Number of subjects: 30
Study 22984910 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) with compression bandage (complex decongestive therapy)
Number of subjects: 30
Study 19145115 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 218
Study 19145115 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 218
Study 17320553 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics
Number of subjects: 485
Study 17320553 — intervention group
Group type: COMPARATOR
Intervention: St. Jude Medical
Number of subjects: 485
Study 15346750 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisional restoration of Osseotite implants
Number of subjects: 38
Study 11334210 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucofiltration (LF)
Number of subjects: 24
Study 11334210 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (CT)
Number of subjects: 24
Study 9675433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine-lidocaine-phenylephrine (TetraLidoPhen)
Number of subjects: 90
Study 9675433 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 90
Study 8120217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil F2/etching
Number of subjects: 201
Study 8120217 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia EX/sandblasting
Number of subjects: 201
Study 8120217 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfill Pontic C/silicate-coating
Number of subjects: 201
Study 8120217 — intervention group
Group type: EXPERIMENTAL
Intervention: General dental practices
Number of subjects: 201
Study 8120217 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary PRBBs
Number of subjects: 201
Study 8120217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular PRBBs
Number of subjects: 201